SEC Filing Timeline
Recent News (Finnhub)
COMPASS Pathways (CMPS) Could Be 62% Undervalued As FDA Filing Sharpens The Case
Compass Pathways Completes FDA Application for Psilocybin Therapy, Prepares for Launch
AstraZeneca buys vaccine startup; FDA issues GLP-1 safety warning
Compass Pathways to Participate in Jefferies Global Healthcare Conference on November 18th and 19th
Compass Pathways PLC (CMPS) (Q3 2026) Earnings Call Highlights: $444 Million Cash Runway, FDA ...
Cybin Expects Key Phase III Depression Trial Results This Quarter
Compass Pathways could secure US approval for depression drug by early 2027, Jefferies says
Compass Pathways stock gains on FDA filing for depression drug